Skip to the content

FDA Medical Device Recalls (openFDA)

Siemens Healthcare Diagnostics, Inc: Centaur Syphilis Assay-SYP Kit, 200 Test - Product Usage: For in vitro diagnostic use in the qualitative determination of antibodies to Treponema pallidum in human serum or plasma using the ADVIA Centaur XP/XPT System and ADVIA Centaur CP Systems, SMN:10492493

Recall number
Z-1674-2021
Recalling firm
Siemens Healthcare Diagnostics, Inc
Product
Centaur Syphilis Assay-SYP Kit, 200 Test - Product Usage: For in vitro diagnostic use in the qualitative determination of antibodies to Treponema pallidum in human serum or plasma using the ADVIA Centaur XP/XPT System and ADVIA Centaur CP Systems, SMN:10492493
Status
Open, Classified
Initiated
2021-04-21
Posted
not on file
Terminated
not on file
Reason
Potential for the ADVIA Centaur Syphilis assay to carryover into other commercial assays. This carryover effect only occurs when the impacted assays are used immediately following testing with the Syphilis assay on the ADVIA Centaur XP/XPT or ADVIA Centaur CP systems
Root cause
Device Design
Action
Siemens issued Urgent Medical Device Correction (UMDC) to US affected customers via FedEx beginning on 04/21/2021. An Urgent Field Safety Notice (UFSN) was issued to all OUS Siemens sites with affected customers electronically for distribution and regional reporting to their local competent authorities beginning on 04/21/2021. Letter states reason for recall, health risk and Actions to be Taken by the Customer: Please review this letter with your Medical Director. If you have multiple ADVIA Centaur XP/XPT or ADVIA Centaur CP systems: Siemens recommends testing the ADVIA Centaur Syphilis assay on a separate system from the impacted ADVIA Centaur assays (ADVIA Centaur PRGE, T4 on the ADVIA Centaur XP/XPT and ADVIA Centaur AFP, COR, PHTN, VALP on the ADVIA Centaur CP) to avoid the potential carryover effect. If you have a single ADVIA Centaur XP/XPT or ADVIA Centaur CP system: It is important to prevent the impacted assays from being processed after the Syphilis assay without a Daily Cleaning Procedure (DCP) run in between. For example, this can be achieved by processing all Syphilis testing, running the DCP, and then proceeding with all other testing including the impacted assays. Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days. If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative. Please retain this letter with your laboratory records and forward this letter to those who may have received this product.
Quantity
22550 units
Distribution
Worldwide distribution - US Nationwide distribution and the countries of Austria, Belgium, Burkina Faso, Croatia, Czech Republic, Egypt, Finland, France, Fren.Polynesia, Georgia, Germany, Germany, Greece, Guadeloupe, Italy, Kazakhstan, Latvia, Netherlands, Norway, Poland, Portugal, Qatar, Russian Fed., Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, U.A.E., Ukraine, United Kingdom.
Lot, serial or model codes
All Lots
510(k) numbers
["K112343"]
PMA numbers
not on file
Product code
LIP
Firm FEI
1219913
Firm city
East Walpole
Firm state
MA
Firm country
not on file

Where this comes from

Register
FDA Medical Device Recalls (openFDA)
Publisher
U.S. Food and Drug Administration (openFDA)
File
device-recall-0001-of-0001.json.zip
sha256
b87518bfe2e8
Size
288210821 bytes
Published
2026-09-28
Read
2026-09-29T08:25:23.626Z
Source file
Source file retained · verify
Refresh due
2026-10-06

Unless otherwise noted, the content, data, documentation, code, and related materials on openFDA is public domain and made available with a Creative Commons CC0 1.0 Universal dedication.

Cite as

FDA Medical Device Recalls (openFDA) (U.S. Food and Drug Administration (openFDA)), device-recall-0001-of-0001.json.zip, sha256 b87518bfe2e8, published 2026-09-28

Search this register